SBIR Phase I: Novel Method for In Situ Polymerase Chain Reaction (PCR)

SBIR 第一阶段：原位聚合酶链式反应 (PCR) 的新方法

• 批准号: 0214861
• 负责人: Jan Trnovsky
• 金额: $ 10万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0214861&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Method; Situ

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a sensitive and rapid method for detecting rare cells infected with viruses. Although PCR (Polymerase Chain Reaction) has revolutionized nucleic acid detection, leakage of amplicons from cells during thermocycling, an inherent problem in conventional procedures, limits its use for in situ PCR applications. Furthermore, microscopic visualization after in situ PCR is tedious and not amenable to rare cell detection. Development of a rapid method to identify and quantify activation of genes involved in viral infection and tumorigenesis in single rare cells would significantly benefit both research as well as clinical applications such as diagnosis and therapeutic staging. The Phase I research will develop the assay using model cell lines infected with the human T-cell leukemia virus type I.The commercial applications of this project will be in the area of diagnostics linked to the managemement of genetically based diseases.

这个小型企业创新研究(SBIR)第一阶段项目建议开发一种敏感而快速的方法来检测感染病毒的稀有细胞。尽管聚合酶链式反应(PCR)使核酸检测发生了革命性的变化，但热循环过程中细胞内扩增产物的泄漏，这是传统方法中的一个固有问题，限制了其在原位PCR应用中的应用。此外，原位聚合酶链式反应后的显微可视化是繁琐的，不适合稀有细胞的检测。发展一种快速识别和量化单个稀有细胞中与病毒感染和肿瘤发生有关的基因激活的方法将对诊断和治疗分期等研究和临床应用具有重要意义。第一阶段的研究将使用感染I型人类T细胞白血病病毒的模型细胞系开发这种分析方法。该项目的商业应用将在与遗传性疾病管理相关的诊断领域。